Results 251 to 260 of about 76,888,029 (302)
Subclinical neurovascular and immune correlates of post-COVID-19 syndrome detected by retinal imaging. [PDF]
Wunderle M +14 more
europepmc +1 more source
Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel +18 more
wiley +1 more source
Disrupted fluid homeostasis in patients with post-Covid-19 syndrome - a case series. [PDF]
Huhmar H +4 more
europepmc +1 more source
IgG Glycosylation‐Dependent CLEC7A Signaling Drives Podocyte Dysfunction in Lupus Nephritis
Objective Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) that can lead to end‐stage kidney disease and increased mortality. IgG from patients with LN displays abnormal glycosylation, contributing to podocyte injury.
Rohit Upadhyay +3 more
wiley +1 more source
Functional consequences of post-COVID-19 syndrome: Evidence from Qatar, 2022. [PDF]
Adli N, Selim N.
europepmc +1 more source
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf +15 more
wiley +1 more source
Presence of post-COVID-19 condition in six ethnic groups in Amsterdam, the Netherlands: a retrospectively reconstructed time interval approach. [PDF]
Spronk M +10 more
europepmc +1 more source
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease +20 more
wiley +1 more source
Determinants of influenza vaccination in a French primary care population in the post-COVID-19 era. [PDF]
Mafi S, Billo A, Durieux MF, Hantz S.
europepmc +1 more source

